Quick search
Search Drugs by First Letter
categories / Woman's Health / Bimat
Active Ingredient: Bimatoprost
Bimat decreases intraocular pressure by increasing the outflow of aqueous humor. Bimatoprost may increase the percent and duration of hairs in the growth phase, resulting in eyelash growth.
Other names for this medication
Show all
Analogs of Bimat:
Bimat 3ml
 PackagePer PillPriceSavingsBonusOrder 
3ml × 1 bottles $31.11$31.11+ Cialis 
3ml × 2 bottles $29.38$58.77$3.46+ Levitra 
3ml × 3 bottles $28.81$86.42$6.91+ Viagra 
3ml × 4 bottles $28.52$114.08$10.37+ Cialis 
3ml × 5 bottles $28.35$141.73$13.83+ Levitra 
3ml × 6 bottles $28.23$169.39$17.28+ Viagra 
3ml × 7 bottles $28.15$197.04$20.74+ Cialis 
3ml × 8 bottles $28.09$224.7$24.2+ Levitra 
3ml × 9 bottles $28.04$252.35$27.66+ Viagra 
3ml × 10 bottles $28$280.01$31.11+ Cialis 


Bimat is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: 
Ocular hypertension
Lengthening eyelashes


Elevated intraocular pressure

Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening; do not exceed once-daily dosing (may decrease IOP-lowering effect). If used with other topical ophthalmic agents, separate administration by at least 5 minutes.

Hypotrichosis of the eyelashes (Latisse): Ophthalmic, topical: Place one drop on applicator and apply evenly along the skin of the upper eyelid at base of eyelashes once daily at bedtime; repeat procedure for second eye (use a clean applicator).

Remove make-up and contact lenses prior to application; ensure face is clean. Apply with the sterile applicator provided only; do not use other brushes or applicators. Use a tissue or cloth to blot any excess solution on the outside of the upper eyelid margin; do not apply to lower eyelash line. Do not reuse applicators; use new applicator for second eye. Applying more than once nightly will not increase eyelash growth; eyelash growth is expected to return to baseline when therapy is discontinued. May reinsert contacts 15 minutes after application.


Please consult a doctor regarding the dosage. Patients receiving medications to reduce intraocular pressure should consult their healthcare provider prior to using; may interfere with desired reduction of intraocular pressure.


Store between 2°C to 25°C (36°F to 77°F).


Concerns related to adverse effects:

• Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.

• Ocular effects: May permanently change/increase brown pigmentation of the iris, the eyelid skin, periorbital tissue, and eyelashes. In addition, may increase the length, thickness, and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences of increased pigmentation are not known.

• Ocular inflammation: Intraocular inflammation and exacerbation of inflammation may occur; use with caution in patients with active intraocular inflammation (eg, uveitis).

Disease-related concerns:

• Ocular disease: Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy of Lumigan have not been determined for use in patients with angle-closure-, inflammatory-, or neovascular glaucoma.

Special populations:

• Contact lens wearers: Contains benzalkonium chloride which may be adsorbed and cause discoloration of soft contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.

Dermatologic: Increased growth in number of eyelashes

Ophthalmic: Conjunctival hyperemia (25% to 45%; Latisse: <4%), eye pruritus (>10%; Latisse: <4%)

1% to 10%:

Central nervous system: Headache (1% to 5%), foreign body sensation of eye

Dermatologic: Erythema of eyelid (1% to 10%; Latisse: <4%), skin hyperpigmentation (Latisse: <4%), hyperpigmentation of eyelashes, pigmentation of the periocular skin

Endocrine & metabolic: Hirsutism

Hepatic: Abnormal hepatic function tests (1% to 5%)

Infection: Infection (10% [primarily colds and upper respiratory tract infections])

Neuromuscular & skeletal: Weakness (1% to 5%)

Ophthalmic: Dry eye syndrome (1% to 10%; Latisse: <4%), eye irritation (1% to 10%; Latisse: <4%), allergic conjunctivitis, asthenopia, blepharitis, burning sensation of eyes, cataract, conjunctival edema, conjunctival hemorrhage, eye discharge, eye pain, iris hyperpigmentation (may be delayed), lacrimation, photophobia, superficial punctate keratitis, visual disturbance

<1% (Limited to important or life-threatening): Hair breakage, hypersensitivity reaction, hypertension, iritis, macular edema, madarosis, skin rash.

Change language
Shopping cart
Copyright © 2004-2024 All Rights Reserved